サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1481920

北米の乳がん治療：2030年までの市場予測 - 地域分析 - 薬物療法、乳がんタイプ、流通チャネル別

North America Breast Cancer Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Therapy, Breast Cancer Type, and Distribution Channel

出版日
ページ情報
英文 94 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
北米の乳がん治療：2030年までの市場予測 - 地域分析 - 薬物療法、乳がんタイプ、流通チャネル別
出版日: 2024年03月04日
発行: The Insight Partners
ページ情報: 英文 94 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米の乳がん治療市場は、2022年に133億4,687万米ドルと評価され、2030年には270億1,492万米ドルに達すると予測され、2022年から2030年までのCAGRは9.2%で成長すると予測されています。

個別化医療利用の増加が北米の乳がん治療市場を後押し

個別化医療とは、患者の遺伝的体質などに基づいて治療計画を個々の患者に合わせることです。このアプローチでは、各患者のがんの特徴を考慮するため、高度に的を絞った効果的な治療が可能になります。ゲノミクスと分子診断学の進歩により、個別化医療は乳がん治療において実行可能な選択肢となった。ヘルスケアプロバイダーは、患者の腫瘍を分子レベルで分析することにより、がんの成長を促す特定の遺伝子変異やバイオマーカーを特定することができます。この情報をもとに、標的療法や免疫療法など、特定の患者にとって最も効果的と思われる治療法を選択することができます。乳がん治療における個別化医療の利用は、患者の転帰を大幅に改善する可能性を秘めています。例えば、2022年2月、NIHの研究者らは、転移性乳がん患者の治療に腫瘍と闘う免疫細胞を使用する免疫療法の実験的形態である個別化乳がん治療アプローチを開発し、個別化医療を進展させました。

個々の患者に合わせた治療法を提供することで、ヘルスケアプロバイダーは治療が成功する可能性を高め、不必要な副作用のリスクを減らすことができます。患者の転帰を改善するだけでなく、個別化医療には経済的なメリットもあります。より効果が期待できる治療法を選択することで、ヘルスケアプロバイダーは効果のない治療に伴う医療費を削減し、不必要な出費を避けることができます。ゲノミクスと分子診断学の進歩に伴い、個別化医療は今後ますます利用しやすくなり、標準的な治療プロトコルに組み込まれるようになると思われます。そのため、個別化医療の利用の増加は、北米の乳がん治療市場に新たな成長動向をもたらすと予想されます。

北米の乳がん治療市場概要

北米の乳がん治療市場は、米国、カナダ、メキシコに区分され、この地域では米国が最大の市場シェアを占めています。市場の成長は主にこの地域に起因しており、乳がん有病率の上昇や新規治療法開発のための研究開発投資の増加などの要因により、安定した成長が見込まれています。加えて、北米諸国に拠点を拡大する市場参入企業も増えています。

医療技術と研究の向上は、患者の予後を改善する画期的な治療法の創出に火をつけた。米国では、ファイザー、ノバルティス、ロシュ、アストラゼネカ、イーライリリーなどの大手製薬会社が乳がん治療市場を独占しています。これらの企業は、新薬や改良薬を市場に投入するため、研究開発に多額の投資を行っています。政府による規制と政策も市場に影響を与えています。乳がん治療のための新薬や治療法は、食品医薬品局（FDA）の政府機関によって承認されます。今後数年間で、乳がん治療市場はさらに拡大すると予想されます。

北米の乳がん治療市場の収益と2030年までの予測（金額）

北米の乳がん治療市場セグメンテーション

北米の乳がん治療市場は、薬物療法、乳がんタイプ、流通チャネルに基づいて細分化されます。

薬物療法に基づいて、北米の乳がん治療市場は標的薬物療法、ホルモン薬物療法、化学療法、免疫療法/生物学的療法に区分されます。2022年には標的薬物療法分野が大きなシェアを占めています。標的薬物療法セグメントはさらに、アベマシクリブ、アドトラスツズマブ・エムタンシン、パルボシクリブ、トラスツズマブ、その他の標的薬物療法に細分化されます。さらに、ホルモン薬物療法セグメントは、選択的エストロゲン受容体モジュレーター、アロマターゼ阻害剤、選択的エストロゲン受容体ダウンレギュレーターに分類されます。

乳がんのタイプ別では、北米の乳がん治療市場はホルモン受容体、HER2+、トリプルネガティブ乳がんに区分されます。2022年にはホルモン受容体セグメントが大きなシェアを占めています。

流通チャネル別では、北米の乳がん治療市場は病院薬局、ドラッグストア・小売薬局、オンライン薬局に区分されます。2022年には病院薬局セグメントが大きなシェアを占めています。

国別に見ると、北米の乳がん治療市場は米国、カナダ、メキシコに分類されます。2022年の北米の乳がん治療市場は米国が支配的でした。

Eli Lilly and Co、Eisai Co Ltd、Novartis AG、AstraZeneca Plc、Pfizer Inc、Gilead Sciences Inc、Merck &Co Inc、Genentech Inc、Teva Pharmaceutical Industries Ltd、Amgen Incは、北米の乳がん治療市場で事業を展開している大手企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 北米の乳がん治療市場- 主要産業ダイナミクス

  • 主な市場促進要因
    • 乳がんの負担増
    • 複数の診断およびスクリーニングプログラムの開始
  • 主な市場抑制要因
    • 診断と治療にかかるコストの高さ
  • 主な市場機会
    • 政府および民間団体からの支援の増加
  • 主な将来動向
    • 個別化医療の利用の増加
  • 影響分析

第5章 乳がん治療市場：北米市場分析

  • 北米の乳がん治療市場収益、2022年～2030年

第6章 北米の乳がん治療市場 - 収益と2030年までの予測：薬物療法別

  • 市場収益シェア、2022年および2030年
  • 標的薬物療法
  • ホルモン薬物療法
  • 化学療法
  • 免疫療法/生物学的療法

第7章 北米の乳がん治療市場 - 収益と2030年までの予測：乳がんタイプ別

  • 市場収益シェア、2022年および2030年
  • ホルモン受容体
  • HER2+（ヒト上皮成長因子受容体2）
  • トリプルネガティブ乳がん

第8章 北米の乳がん治療市場 - 収益と2030年までの予測：販売チャネル別

  • 市場収益シェア、2022年および2030年
  • 病院薬局
  • ドラッグストアおよび小売薬局
  • オンライン薬局

第9章 北米の乳がん治療市場：地域分析

  • 北米の乳がん治療市場、2030年までの収益と予測
    • 北米の乳がん治療市場：国別内訳、収益（2022年）
    • 北米の乳がん治療市場：国別
      • 米国
      • カナダ
      • メキシコ

第10章 乳がん治療市場：業界情勢

  • 乳がん治療市場における成長戦略
  • 有機的成長戦略
  • 無機的成長戦略

第11章 企業プロファイル

  • Eli Lilly and Co
  • Eisai Co Ltd
  • Novartis AG
  • AstraZeneca Plc
  • Pfizer Inc
  • Gilead Sciences Inc
  • Merck & Co Inc
  • Teva Pharmaceutical Industries Ltd
  • Amgen Inc
  • Amgen Inc

第12章 付録

図表

List Of Tables

  • Table 1. North America Breast Cancer Therapeutics Market Segmentation
  • Table 2. North America Breast Cancer Therapeutics Market, by Targeted Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. North America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. US Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. US Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. US Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. US Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. US Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. Canada Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. Canada Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Canada Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Canada Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 13. Canada Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 14. Mexico Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 15. Mexico Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. Mexico Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
  • Table 17. Mexico Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 18. Mexico Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 19. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
  • Table 20. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
  • Table 21. Glossary of Terms, Breast Cancer Therapeutics Market

List Of Figures

  • Figure 1. North America Breast Cancer Therapeutics Market Segmentation, By Country
  • Figure 2. North America Breast Cancer Therapeutics Market - Key Industry Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. North America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
  • Figure 5. North America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
  • Figure 6. Targeted Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Hormonal Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Chemotherapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Immunotherapy/ Biological Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. North America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
  • Figure 11. Hormone Receptor: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. HER2+: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Triple-Negative Breast Cancer: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. North America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
  • Figure 15. Hospital Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Drug Store and Retail Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Online Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. North America Breast Cancer Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 19. North America Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
  • Figure 20. US Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 21. Canada Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 22. Mexico Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 23. Growth Strategies in Breast Cancer Therapeutics Market
目次
Product Code: BMIRE00029747

The North America breast cancer therapeutics market was valued at US$ 13,346.87 million in 2022 and is expected to reach US$ 27,014.92 million by 2030; it is estimated to grow at a CAGR of 9.2% from 2022 to 2030.

Increasing Use of Personalized Medicine Fuels the North America Breast Cancer Therapeutics Market

Personalized medicine involves tailoring treatment plans to individual patients on the basis of their genetic makeup, among other factors. This approach allows for highly targeted and effective treatments, as it considers the unique characteristics of each patients cancer. Advancements in genomics and molecular diagnostics have made personalized medicine a viable option in breast cancer treatment. Healthcare providers can identify specific genetic mutations or biomarkers driving the cancers growth by analyzing a patients tumor at a molecular level. This information can then be used to select the most appropriate treatment options, such as targeted therapies or immunotherapies, that are likely to be the most effective for that particular patient. The use of personalized medicine in breast cancer therapeutics has the potential to significantly improve patient outcomes. For instance, in February 2022, NIH researchers developed a personalized breast cancer therapy approach, an experimental form of immunotherapy that uses a patients tumor-fighting immune cells to treat those with metastatic breast cancer, advancing personalized medicine.

By providing tailored treatments to individual patients, healthcare providers can increase the likelihood of successful outcomes and reduce the risk of unnecessary side effects. In addition to improving patient outcomes, personalized medicine also offers economic benefits. By selecting treatments that are more likely to be effective, healthcare providers can reduce healthcare costs associated with ineffective treatments and avoid unnecessary expenses. As advancements in genomics and molecular diagnostics progress, personalized medicine is likely to become increasingly accessible and integrated into standard treatment protocols in the coming years. Therefore, the increasing use of personalized medicine is anticipated to bring new growth trends in the North America breast cancer therapeutics market.

North America Breast Cancer Therapeutics Market Overview

The breast cancer therapeutics market in North America is segmented into the US, Canada, and Mexico; the US holds the largest market share in this region. The market growth is mainly attributed to the region, which is expected to witness consistent growth owing to factors such as the rising prevalence of breast cancer and rising R&D investments for developing novel treatments. In addition, a growing number of market players are expanding their geographical footprint in North American countries.

Improvements in medical technology and research have sparked the creation of ground-breaking treatments that can enhance patient outcomes. Several large pharmaceutical companies, including Pfizer, Novartis, Roche, AstraZeneca, and Eli Lilly, dominate the therapeutic market for breast cancer in the US. These businesses make significant investments in research and development to introduce novel and enhanced medicines to the market. Regulations and policies put in place by the government also affect the market. New medications and therapies for breast cancer treatment are approved by the government agencies of the Food and Drug Administration (FDA). In the upcoming years, the therapeutic market for breast cancer is anticipated to expand further.

North America Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

North America Breast Cancer Therapeutics Market Segmentation

The North America breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.

Based on drug therapy, the North America breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.

In terms of breast cancer type, the North America breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.

By distribution channel, the North America breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.

Based on country, the North America breast cancer therapeutics market is categorized into US, Canada, and Mexico. The US dominated the North America breast cancer therapeutics market in 2022.

Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Genentech Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc are some of the leading companies operating in the North America breast cancer therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Breast Cancer Therapeutics Market - Key Industry Dynamics

  • 4.1 Key Market Drivers
    • 4.1.1 Growing Burden of Breast Cancer
    • 4.1.2 Launch of Several Diagnostics and Screening Programs
  • 4.2 Key Market Restraints
    • 4.2.1 High Cost of Diagnosis and Treatment
  • 4.3 Key Market Opportunities
    • 4.3.1 Increased Support from Government and Private Organizations
  • 4.4 Key Future Trends
    • 4.4.1 Increasing Use of Personalized Medicine
  • 4.5 Impact Analysis:

5. Breast Cancer Therapeutics Market - North America Market Analysis

  • 5.1 North America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030

6. North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Drug Therapy

  • 6.1 Overview
  • 6.2 North America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
  • 6.3 Targeted Drug Therapy
    • 6.3.1 Overview
    • 6.3.2 Targeted Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.3.2.1 North America Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
  • 6.4 Hormonal Drug Therapy
    • 6.4.1 Overview
    • 6.4.2 Hormonal Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.4.2.1 North America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
  • 6.5 Chemotherapy
    • 6.5.1 Overview
    • 6.5.2 Chemotherapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.6 Immunotherapy/ Biological Therapy
    • 6.6.1 Overview
    • 6.6.2 Immunotherapy/ Biological Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Breast Cancer Type

  • 7.1 Overview
  • 7.2 North America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
  • 7.3 Hormone Receptor
    • 7.3.1 Overview
    • 7.3.2 Hormone Receptor: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 HER2+ (human epidermal growth factor receptor 2)
    • 7.4.1 Overview
    • 7.4.2 HER2+: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Triple-Negative Breast Cancer
    • 7.5.1 Overview
    • 7.5.2 Triple-Negative Breast Cancer: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Distribution Channel

  • 8.1 Overview
  • 8.2 North America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
  • 8.3 Hospital Pharmacies
    • 8.3.1 Overview
    • 8.3.2 Hospital Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Drug Store and Retail Pharmacies
    • 8.4.1 Overview
    • 8.4.2 Drug Store and Retail Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Online Pharmacies
    • 8.5.1 Overview
    • 8.5.2 Online Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Breast Cancer Therapeutics Market - Regional Analysis

  • 9.1 North America Breast Cancer Therapeutics Market, Revenue and Forecast To 2030
    • 9.1.1 Overview
    • 9.1.2 North America Breast Cancer Therapeutics Market, Breakdown, by Country, Revenue (2022) (US$ Million)
    • 9.1.3 North America Breast Cancer Therapeutics Market, by Country
      • 9.1.3.1 US
        • 9.1.3.1.1 US Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.1.2 US: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.1.2.1 US: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.1.2.2 US: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.1.3 US: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
        • 9.1.3.1.4 US: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.3.2 Canada
        • 9.1.3.2.1 Canada Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.2.2 Canada: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.2.2.1 Canada: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.2.2.2 Canada: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.2.3 Canada: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
        • 9.1.3.2.4 Canada: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.3.3 Mexico
        • 9.1.3.3.1 Mexico Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.3.2 Mexico: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.3.2.1 Mexico: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.3.2.2 Mexico: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
        • 9.1.3.3.3 Mexico: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
        • 9.1.3.3.4 Mexico: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Breast Cancer Therapeutics Market-Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in Breast Cancer Therapeutics Market
  • 10.3 Organic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Inorganic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Eli Lilly and Co
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Eisai Co Ltd
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Novartis AG
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 AstraZeneca Plc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Pfizer Inc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Gilead Sciences Inc
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Merck & Co Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Teva Pharmaceutical Industries Ltd
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Amgen Inc
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 Amgen Inc
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About Us
  • 12.2 Glossary of Terms